Barrington James’ Post

Explore the innovative world of ophthalmology clinical trials with Amy Del Medico, Vial’s VP of Ophthalmology, as she shares insights on electronic data capture, patient recruitment challenges, and selecting the right CRO partner for your trial. Watch the video here: https://lnkd.in/gRwcNSyW

We delve into the significance of a holistic approach in ophthalmology clinical trials and why patient-centricity and diversity are paramount. Read on-> https://lnkd.in/eYyaSvgB #clinicalresearch #ophthalmology #recruitment #diversity

"If done correctly, these types of trials can have an overall positive impact on ophthalmology studies." Richard Zink, PhD, along with David Wirta, MD of the Eye Research Foundation, discuss the benefits and limitations of DCT in ophthalmic trials. ___________________________ #lifesciences #clinicaltrials #ophthalmology

🔍👁️ Big news in the world of eye health! This insightful article delves into the evolving trends in age-related macular degeneration (AMD) treatment. From innovative therapies to personalized approaches, it's an exciting time for AMD patients and the field of ophthalmology. Learn about the potential shifts that could revolutionize care for those with AMD: https://brnw.ch/21wDGpg

#AAO2023: The GALE study (ClinicalTrials. gov Identifier: NCT04770545) shows that geographic atrophy treatment with pegcetacoplan can reduce lesion sizes by 24% to 35% between months 24 and 36 of treatment, according to Charles Wykoff, MD (of Retina Consultants of Texas, Blanton Eye Institute of Houston Methodist, and Weill Cornell Medicine) who presented the findings at the 2023 American Academy of Ophthalmology meeting in San Francisco, November 3 to 6. The analysis also shows that the drug’s efficacy likely increases with more treatments. Read here: https://brnw.ch/21wEleR #GALEStudy #NCT04770545 #GeographicAtrophy #EyeHealth #EyeCare #GeographicAtrophyTreatment #Pegecetacoplan #EyeLesion #Ophthalmology #ClinicalTrials #EyeResearch #HCSM

👁️✨ Revolutionizing Glaucoma Treatment: Ciliatech Unveils Enhanced CID Device Amidst Patent Boost! 🌟🔬 BusinessToday.News is thrilled to bring you a groundbreaking advancement in the field of healthcare and technology! 📰💡 📌 Article Link: https://lnkd.in/eH6v4Zeb 🔍 Imagine a world where glaucoma patients have access to cutting-edge treatment. This article reveals how Ciliatech is leading the way with their Enhanced CID Device, amidst a significant patent boost: 👁️ Transforming the landscape of glaucoma care with innovative technology. 🔬 Providing hope to millions of patients worldwide. 📊 Elevating the standard of eye health and treatment. 🌐 Pioneering advancements in the field of ophthalmology. 🔥 Don't miss this opportunity to learn about Ciliatech's remarkable contribution to improving the lives of glaucoma patients and advancing the future of eye care! 📌 Article Link: Revolutionary Glaucoma Treatment: Ciliatech Unveils Enhanced CID Device Amidst Patent Boost 👉 Join the conversation and share your thoughts on the significance of innovation in healthcare and its impact on patients' lives in the comments section of the article. Let's celebrate progress together! 🗣️👁️ #GlaucomaTreatment #HealthcareInnovation #Ciliatech #EyeCare #BusinessTodayNews #MedicalAdvancements #PatentBoost #Ophthalmology #RevolutionaryTech

iPeer Review! 🔖 Pam Theriot, OD, FAAO reviews results of the Cequa Phase 4 study. The phase 4 Cequa cyclosporine 0.09% solution study reveals that patients 👭who did not respond to cyclosporine 0.05% for over three months can successfully switch to 0.09%, showing significant improvement in both signs and symptoms. Conducted over 12 weeks, this multi-center🏢 study highlights the benefits of BID dosing with 0.09% cyclosporine, including decreased corneal fluorescein stain and improved symptom scores. 👀#dryeye #cequa #eyecare #optometry Refrences: Johnston, J. Effect of OTX-101 0.09% on corneal staining and SANDE scores in patients with dry eye disease uncontrolled on cyclosporine ophthalmic emulsion 0.05%. Abstract presented at American Academy of Optometry 2023; October 12, 2023; New Orleans, LA. Ophthalmology 360. "Phase 4 Data Demonstrates CEQUA's Sustained Efficacy in Dry Eye Disease." Available at: https://lnkd.in/eP2Cz_2P Disclosures: Dr. Theriot is a speaker for Sun Pharmaceuticals

A novel patient-reported outcome measure, the Low Vision Severely Constricted Peripheral Eyesight (LV-SCOPE) questionnaire, has been validated in individuals with severe peripheral field loss (PFL), according to research published in American Journal of Ophthalmology. https://brnw.ch/21wCJy5 #LowVisionSeverelyConstrictedPeripheralEyesight #LVSCOPE #EyeHealth #Questionnaire #PeripheralFieldLoss #PFL #Optometry #Optometrist #LowVision #EyeCare

A high myopia-specific normative database of peripapillary retinal nerve fiber layer (pRNFL) thickness more accurately detects glaucoma among eyes with high myopia than the built-in database used in swept-source optical coherence tomography (SS-OCT) devices, according to research published in Ophthalmology (American Academy of Ophthalmology). https://brnw.ch/21wC1h3 #Myopia #PeripapillaryRetinalNerveFiberLayer #pRNFL #pRNFLThickness #SSOCT #MyopiaManagement #Glaucoma #GlaucomaAwareness #Optometry #EyeCare